Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, Cindy Rittenberg, Mary E. Elmer, Carrie Schmidt, Arlene Taylor, Alexandra D. Carides, Judith K. Evans and Kevin J. Horgan Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97
Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11320
In this randomized, controlled clinical trial in patients who received high-dose cisplatin chemotherapy, different 5-day regimens of the neurokinin-1 antagonist aprepitant were given in combination with a standard therapy regimen consisting of a serotonin-3 antagonist (ondansetron) plus dexamethasone. The trial determined that aprepitant 125 mg on Day 1 of chemotherapy followed by aprepitant 80 mg once daily on Days 2–5 was the dose with the most favorable benefit:risk ratio.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field